ATE413180T1 - Methylation-modulierende verbingungen zur intraduktalen behandlung von brustkrebs - Google Patents

Methylation-modulierende verbingungen zur intraduktalen behandlung von brustkrebs

Info

Publication number
ATE413180T1
ATE413180T1 AT02715041T AT02715041T ATE413180T1 AT E413180 T1 ATE413180 T1 AT E413180T1 AT 02715041 T AT02715041 T AT 02715041T AT 02715041 T AT02715041 T AT 02715041T AT E413180 T1 ATE413180 T1 AT E413180T1
Authority
AT
Austria
Prior art keywords
breast cancer
methylation
modulating compounds
intraductal
treatment
Prior art date
Application number
AT02715041T
Other languages
English (en)
Inventor
David Hung
Original Assignee
Cytyc Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytyc Corp filed Critical Cytyc Corp
Application granted granted Critical
Publication of ATE413180T1 publication Critical patent/ATE413180T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT02715041T 2001-03-30 2002-03-27 Methylation-modulierende verbingungen zur intraduktalen behandlung von brustkrebs ATE413180T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27976201P 2001-03-30 2001-03-30
US10/101,631 US20020142941A1 (en) 2001-03-30 2002-03-21 Intraductal treatment targeting methylated promoters in breast cancer

Publications (1)

Publication Number Publication Date
ATE413180T1 true ATE413180T1 (de) 2008-11-15

Family

ID=26798462

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02715041T ATE413180T1 (de) 2001-03-30 2002-03-27 Methylation-modulierende verbingungen zur intraduktalen behandlung von brustkrebs

Country Status (8)

Country Link
US (2) US20020142941A1 (de)
EP (1) EP1372671B1 (de)
JP (2) JP2004525151A (de)
AT (1) ATE413180T1 (de)
AU (1) AU2002247262B2 (de)
DE (1) DE60229727D1 (de)
ES (1) ES2314041T3 (de)
WO (1) WO2002078716A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000076555A1 (en) * 1999-06-11 2000-12-21 Pro Duct Health, Inc. Gel composition for filing a breast milk duct prior to surgical excision of the duct or other breast tissue
US8207381B2 (en) * 2007-02-06 2012-06-26 University Of Louisville Research Foundation Therapeutic compounds
CA2730995C (en) 2008-07-17 2016-11-22 Micell Technologies, Inc. Drug delivery medical device
EP2411083A4 (de) 2009-03-23 2013-11-13 Micell Technologies Inc Medizinische wirkstofffreisetzungsvorrichtung
JPWO2010113529A1 (ja) 2009-04-03 2012-10-04 株式会社エイアンドティー 大腸腫瘍の検出方法
WO2011031561A2 (en) * 2009-08-27 2011-03-17 Ensisheim Partners Llc Nucleic acid molecules and uses thereof
WO2011113047A2 (en) * 2010-03-12 2011-09-15 The Johns Hopkins University Compositions and methods for characterizing breast cancer
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CA3094072A1 (en) * 2018-03-15 2019-09-19 Atossa Therapeutics, Inc. In situ methods of inducing of immune response
CN111363819A (zh) * 2020-01-08 2020-07-03 武汉科技大学 一种利用ddPCR技术联合检测诊断乳腺癌的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5101072A (en) * 1989-09-06 1992-03-31 Yale University Sulfonylhydrazines and their use as antineoplastic agents and as antitrypanosomal agents
US5763415A (en) * 1995-08-03 1998-06-09 John Hopkins University School Of Medicine Destruction of the epithelium of an exocrine gland in the prophylactic and therapeutic treatment of cancer
US5874416A (en) * 1997-11-07 1999-02-23 Sheikhnejad; Gholamreza RAS antisense inhibition
US6255293B1 (en) * 1998-07-24 2001-07-03 Yeda Research And Development Co., Ltd. Prevention of metastasis with 5-aza-2′-deoxycytidine

Also Published As

Publication number Publication date
DE60229727D1 (de) 2008-12-18
ES2314041T3 (es) 2009-03-16
WO2002078716A2 (en) 2002-10-10
AU2002247262B2 (en) 2008-09-04
JP2009096808A (ja) 2009-05-07
US20020142941A1 (en) 2002-10-03
US20050272685A1 (en) 2005-12-08
EP1372671A2 (de) 2004-01-02
WO2002078716A3 (en) 2002-11-21
JP2004525151A (ja) 2004-08-19
EP1372671B1 (de) 2008-11-05

Similar Documents

Publication Publication Date Title
ATE413180T1 (de) Methylation-modulierende verbingungen zur intraduktalen behandlung von brustkrebs
DK1556058T3 (da) Farmaceutiske præparater omfattende östetrolderivater til anvendelse i cancerterapi
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
DK1261367T3 (da) Anvendelse af interleukin-6-antagonister til behandling af östrogenafhængige tumorer
DE60118889D1 (de) Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs
ATE556706T1 (de) Fettalkohol-arzneimittel-konjugate
SI1472541T1 (sl) Prikazovalni agensi in postopek prikazovanja naaladase ali psma
PT1206474E (pt) Compostos de sulfonilfenilpirazole uteis como inibidores de cox-2
EP1844077A4 (de) Dr5-antikörper und deren verwendung
PL360262A1 (pl) Kompozycje polimerycznych micelli
MA42999B1 (fr) Polythérapie contenant ivosidenib, cytarabine et daunorubicin ou idarubicin pour le traitement de la leucémie myéloïde aiguë
HRPK20041072B3 (hr) Primjena docetaxela/doxorubicina/ciklofosfamida uadjuvantnoj terapiji karcinoma dojke i jajnika
BR0010702A (pt) Novas quinonas como terapias de doenças
EA200601524A1 (ru) Альфа-излучающие частицы гидроксиапатита
FR2869540B1 (fr) Compositions pharmaceutiques contenant des derives de b-carboline, et leur utilisation pour le traitement des cancers
IL151448A0 (en) Proteins
EP1694364A4 (de) System zur behandlung und prävention von brustkrebs
DE50211672D1 (de) Urokinase-inhibitoren
DE60032333D1 (de) Zusammensetzungen und verfahren zur intraductalen gentherapie
ATE298328T1 (de) Taxan-derivate für die behandlung von krebs
ATE302009T1 (de) Ubichinon qn zur behandlung von migräneschmerzen
ATE544492T1 (de) Alpha- und beta-emittierende hydroxyapatit- teilchen
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
PL353881A1 (en) Medicaments that contain xenogenic oligo- or/and polyribonucleotides
WO2005048956A3 (en) Estradiol-related compounds and methods of use as anti-tumor agents

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties